Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2019 · 10-Q
Revenue$190.60M$190.60M+61.8% vs Q1 2018 Net Income-$26.10M-$26.10MN/M vs Q1 2018 EPS Diluted-$0.51-$0.51N/M vs Q1 2018 Gross Profit-$27,400,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow$104,800,000N/M Free Cash Flowderived$83,400,000N/M Margins · derivedGross margin-14.4%−6.3 pt vs Q1 2018
Operating margin-14.4%−6.3 pt vs Q1 2018
Net margin-13.7%−9.5 pt vs Q1 2018
ended Mar 31, 2019 · filed May 8, 2019 · 38 d after period end